Resumen
El tratamiento de los trastornos del humor incluye el uso de antidepresivos y de estabilizadores del humor en el trastorno bipolar y, en algunos casos, de depresión resistente. El tratamiento debe ser acorde con la gravedad, personalizado para cada caso, integrador y basado en la evidencia científica. Las medidas terapéuticas incluyen también pautas higiénico-dietéticas, ejercicio físico, psicoterapia, rehabilitación funcional y, en ocasiones, terapia electroconvulsiva. Este protocolo incluye algoritmos, tablas y figuras con el objetivo de facilitar la decisión del tratamiento farmacológico a emplear.
Palabras clave
Depresión
Trastorno bipolar
Antidepresivos
Eutimizantes
Abstract
The treatment of mood disorders includes the use of antidepressants and mood stabilizers in bipolar disorder and, in some cases, treatment-resistant depression. Treatment must be in accordance with severity, personalized for each case, comprehensive, and based on scientific evidence. Therapeutic measures also include hygiene and dietary measures, physical exercise, psychotherapy, functional rehabilitation, and, on occasion, electroconvulsive therapy. This protocol includes algorithms, tables, and figures with the aim of facilitating the decision on which pharmacological treatment to use.
Keywords
Depression
Bipolar disorder
Antidepressants
Mood stabilizers
Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[2]
Manual de depresión, Grupo Aula Médica,
[3]
Major depressive disorder.
Nat Rev Dis Primers., (2016), 2 pp. 16065
[4]
R.S. McIntyre , M. Berk, E. Brietzke, B.I. Goldstein, C. López-Jaramillo, L.V. Kessing, et al.
Bipolar disorders.
Lancet., (2020), 396 pp. 1841-1856
[7]
How should primary care doctors select which antidepressants to administer?.
Curr Psychiatry Rep., (2012), 14 pp. 360-369
[8]
Lancet, (2018), 392 pp. 2299-2312
[9]
A. Cipriani , T.A. Furukawa, G. Salanti, A. Chaimani, L.Z. Atkinson, Y. Ogawa, et al.
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Lancet., (2018), 391 pp. 1357-1366
[16]
Thase M, Connolly R. Unipolar depression in adults: Choosing treatment for resistant depression. UpToDate 2020. Disponible en: www.update.com.
[17]
If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.
Drugs., (2011), 71 pp. 43-64
[18]
CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological Treatments.
Can J Psychiatry., (2016), 61 pp. 540-560
[19]
V. Pérez Sola , D. Puigdemont, L. Mora, P. Álvarez, F.J. De Diego.
Depresión mayor unipolar y resistencia al tratamiento.
In: Depresiones Bipolares y Unipolares Qué hacer en los pacientes que no responden suficientemente a los tratamientos habituales, Editorial Médica Panamericana;, (2019), pp. 13-32
[20]
Ann Med [Internet]., (2011), 43 pp. 512-530
[21]
R. Strawbridge , B. Carter, L. Marwood, B. Bandelow, D. Tsapekos, V.L. Nikolova, et al.
Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis.
Br J Psychiatry., (2019), 214 pp. 42-51
[22]
A. Cleare , C.M. Pariante, A.H. Young, I.M. Anderson, D. Christmas, P.J. Cowen, et al.
Members of the Consensus Meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.
J Psychopharmacol., (2015), 29 pp. 459-525
[24]
An algorithm for the pharmacological treatment of depression.
Acta Psychiatr Scand., (2010), 121 pp. 180
[26]
Interventions to improve medication adherence: A review.
JAMA., (2018), 320 pp. 2461-2473
[27]
S.R. Wisniewski , M. Fava, M.H. Trivedi, M.E. Thase, D. Warden, G. Niederehe, et al.
Acceptability of second-step treatments to depressed outpatients: A STAR*D report.
Am J Psychiatry., (2007), 164 pp. 753-760
[28]
R.M.A. Hirschfeld , S.A. Montgomery, E. Aguglia, M. Amore, P.L. Delgado, M. Gastpar, et al.
Partial response and nonresponse to antidepressant therapy: Current approaches and treatment options.
J Clin Psychiatry., (2002), 63 pp. 826-837
[29]
Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.
J Clin Psychiatry., (2006), 67 pp. 1836-1855
[30]
Sexual dysfunction associated with second generation antidepressants in patients with major depressive disorder: Results from a systematic review with network meta-analysis.
Drug Saf., (2014), 37 pp. 19
[33]
QTc prolongation by psychotropic drugs and the risk of torsade de pointes.
Dtsch Arztebl Int., (2011), 108 pp. 687
[34]
BMJ [Internet]., (2018), 363 pp. k5354
[35]
S. Mohamed , G.R. Johnson, P. Chen, P.B. Hicks, L.L. Davis, J. Yoon, et al.
Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment.
JAMA - J Am Med Assoc, (2017), 318 pp. 132-145
[36]
P. Davies , S. Ijaz, C.J. Williams, D. Kessler, G. Lewis, N. Wiles.
Pharmacological interventions for treatment-resistant depression in adults.
Cochrane Database Syst Rev., (2019), 12 pp. CD010557
[37]
A.J. Rush , D. Warden, S.R. Wisniewski, M. Fava, M.H. Trivedi, B.N. Gaynes, et al.
STAR*D.
CNS Drugs, (2009), 23 pp. 627-647
[38]
A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult chinese patients with treatment-resistant major depression.
J Clin Psychopharmacol., (2011), 31 pp. 638-642
[39]
Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
J Affect Disord., (2013), 151 pp. 209-219
[40]
Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials.
J Psychopharmacol., (2013), 27 pp. 740-758
[41]
Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial.
JAMA Psychiatry., (2018), 75 pp. 139-148
[42]
Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study.
Am J Psychiatry [Internet]., (2018), 175 pp. 620-630
[43]
G. Sanacora , M.A. Frye, W. McDonald, S.J. Mathew, M.S. Turner, A.F. Schatzberg, et al.
American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
JAMA Psychiatry, (2017), 74 pp. 399-405
[44]
L.N. Yatham , S.H. Kennedy, S.V. Parikh, A. Schaffer, D.J. Bond, B.N. Frey, et al.
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Bipolar Disord., (2018), 20 pp. 97-170
[45]
Acta Psychiatr Scand., (2020), 142 pp. 173-192
